## Michael Nagler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9249487/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood, 2016, 127, 546-557.	1.4	112
2	Diagnostic accuracy of a SARS-CoV-2 rapid antigen test in real-life clinical settings. International Journal of Infectious Diseases, 2021, 109, 118-122.	3.3	82
3	Thromboprophylaxis and laboratory monitoring for in-hospital patients with Covid-19 - a Swiss consensus statement by the Working Party Hemostasis. Swiss Medical Weekly, 2020, 150, w20247.	1.6	77
4	Fondaparinux – data on efficacy and safety in special situations. Thrombosis Research, 2012, 129, 407-417.	1.7	75
5	Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction. Circulation, 2020, 142, 441-454.	1.6	67
6	Thrombin generation measurement using the ST Genesia Thrombin Generation System in a cohort of healthy adults: Normal values and variability. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 758-768.	2.3	47
7	Diagnostic utility of the ISTH bleeding assessment tool in patients with suspected platelet function disorders. Journal of Thrombosis and Haemostasis, 2019, 17, 1104-1112.	3.8	42
8	Clinical and laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Thrombosis and Haemostasis, 2016, 116, 823-834.	3.4	41
9	Impact of changes in haematocrit level and platelet count on thromboelastometry parameters. Thrombosis Research, 2013, 131, 249-253.	1.7	36
10	A case of EDTA-dependent pseudothrombocytopenia: simple recognition of an underdiagnosed and misleading phenomenon. BMC Clinical Pathology, 2014, 14, 19.	1.8	35
11	Accuracy of serological testing for SARSâ€CoVâ€2 antibodies: First results of a large mixedâ€method evaluation study. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 853-865.	5.7	34
12	Prospective evaluation of the interobserver reliability of the 4Ts score in patients with suspected heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2012, 10, 151-152.	3.8	33
13	Thromboembolism in patients with congenital afibrinogenaemia. Thrombosis and Haemostasis, 2016, 116, 722-732.	3.4	32
14	Comparative effectiveness and safety of anticoagulants for the treatment of heparinâ€induced thrombocytopenia. American Journal of Hematology, 2021, 96, 805-815.	4.1	29
15	Impact of rivaroxaban on point-of-care assays. Thrombosis Research, 2017, 153, 65-70.	1.7	26
16	Patient Self-Management of Oral Anticoagulation with Vitamin K Antagonists in Everyday Practice: Efficacy and Safety in a Nationwide Long-Term Prospective Cohort Study. PLoS ONE, 2014, 9, e95761.	2.5	25
17	Association of anemia and hemoglobin decrease during acute stroke treatment with infarct growth and clinical outcome. PLoS ONE, 2018, 13, e0203535.	2.5	25
18	A universal antiâ€Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation. British Journal of Haematology, 2021, 193, 1203-1212.	2.5	24

MICHAEL NAGLER

#	Article	IF	CITATIONS
19	Accuracy and consistency of antiâ€Xa activity measurement for determination of rivaroxaban plasma levels. Journal of Thrombosis and Haemostasis, 2017, 15, 1576-1583.	3.8	21
20	Consistency of thromboelastometry analysis under scrutiny: Results of a systematic evaluation within and between analysers. Thrombosis and Haemostasis, 2014, 111, 1161-1166.	3.4	20
21	Impact of a productâ€specific reference standard for the measurement of a <scp>PEC</scp> ylated <scp>rFVIII</scp> activity: the Swiss Multicentre Field Study. Haemophilia, 2017, 23, e335-e339.	2.1	20
22	Rivaroxaban in patients with mechanical heart valves: A pilot study. Thrombosis Research, 2020, 186, 1-6.	1.7	20
23	Risk factors for recurrence in deep vein thrombosis patients following a tailored anticoagulant treatment incorporating residual vein obstruction. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 299-309.	2.3	18
24	Next generation viscoelasticity assays in cardiothoracic surgery: Feasibility of the TEG6s system. PLoS ONE, 2018, 13, e0209360.	2.5	18
25	Epistaxis in anticoagulated patients: Fewer hospital admissions and shorter hospital stays on rivaroxaban compared to phenprocoumon. Clinical Otolaryngology, 2018, 43, 103-108.	1.2	17
26	Accuracy of heparin-induced platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thrombosis Research, 2020, 185, 27-30.	1.7	17
27	Variability between laboratories performing coagulation tests with identical platforms: a nationwide evaluation study. Thrombosis Journal, 2013, 11, 6.	2.1	16
28	Thromboelastometry and Thrombelastography Analysis under Normal Physiological Conditions - Systematic Review. Transfusion Medicine and Hemotherapy, 2017, 44, 78-83.	1.6	16
29	Enhanced Thrombolysis by Ultrasound-Assisted Catheter-Directed Thrombolysis and Microbubbles in an In Vitro Model of Iliofemoral Deep Vein Thrombosis. Thrombosis and Haemostasis, 2019, 119, 1094-1101.	3.4	16
30	Andexanet Alfa–Induced Heparin Resistance: When Anticoagulation Really Remains Reversed. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 908-909.	1.3	16
31	Short-term recovery pattern of plasma fibrinogen after cardiac surgery: A prospective observational study. PLoS ONE, 2018, 13, e0201647.	2.5	15
32	Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2019, 27 48	2.6	15
33	Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans. British Journal of Clinical Pharmacology, 2021, 87, 1466-1474.	2.4	15
34	Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy. RMD Open, 2022, 8, e002166.	3.8	15
35	Rapid immunoassays for diagnosis of heparin-induced thrombocytopenia: Comparison of diagnostic accuracy, reproducibility, and costs in clinical practice. PLoS ONE, 2017, 12, e0178289.	2.5	14
36	Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 159, 103238.	4.4	14

MICHAEL NAGLER

#	Article	IF	CITATIONS
37	How I manage patients with anticoagulation-associated bleeding or urgent surgery. Swiss Medical Weekly, 2018, 148, w14598.	1.6	14
38	Predictors of anticoagulation quality in 15Â834 patients performing patient selfâ€management of oral anticoagulation with vitamin K antagonists in realâ€life practice: a survey of the International Selfâ€Monitoring Association of Orally Anticoagulated Patients. British Journal of Haematology, 2016, 175, 677-685.	2.5	13
39	Retrospective adjustment of self-assessed medical competencies - noteworthy in the evaluation of postgraduate practical training courses. GMS Zeitschrift Für Medizinische Ausbildung, 2012, 29, Doc45.	1.2	13
40	Profile of Instrumentation Laboratory's HemosIL® AcuStar HIT-Ab(PF4-H) assay for diagnosis of heparin-induced thrombocytopenia. Expert Review of Molecular Diagnostics, 2017, 17, 419-426.	3.1	11
41	Accuracy, reproducibility and costs of different laboratory assays for the monitoring of unfractionated heparin in clinical practice: a prospective evaluation study and survey among Swiss institutions. BMJ Open, 2018, 8, e022943.	1.9	11
42	Serological testing for SARSâ€CoVâ€2 antibodies in clinical practice: A comparative diagnostic accuracy study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2090-2103.	5.7	11
43	Theme 2: Epidemiology, Biomarkers, and Imaging of Venous Thromboembolism (and postthrombotic) Tj ETQq1 1	0,784314 1.7	4 rgBT /Over FO
44	How would we treat our own heparin-induced thrombocytopenia during cardiac surgery?. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 1585-1593.	1.3	10
45	Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements. Frontiers in Cardiovascular Medicine, 2021, 8, 717939.	2.4	10
46	Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study. Frontiers in Cardiovascular Medicine, 2022, 9, 817826.	2.4	10
47	Long-term anticoagulation with fondaparinux in a patient with a mechanical heart valve. Annals of Hematology, 2011, 90, 1225-1226.	1.8	9
48	Accuracy of the pointâ€ofâ€care coagulometer CoaguChek XS in the hands of patients. Journal of Thrombosis and Haemostasis, 2013, 11, 197-199.	3.8	9
49	Rapid Centrifugation in the Routine Hemostasis Laboratory. Thrombosis and Haemostasis, 2019, 119, 2025-2033.	3.4	9
50	A high Gas6 level in plasma predicts venous thromboembolism recurrence, major bleeding and mortality in the elderly: a prospective multicenter cohort study. Journal of Thrombosis and Haemostasis, 2019, 17, 306-318.	3.8	9
51	Characteristics, treatment and outcome of bleeding after tooth extraction in patients on DOAC and phenprocoumon compared to non-anticoagulated patients—a retrospective study of emergency department consultations. Clinical Oral Investigations, 2019, 23, 2273-2278.	3.0	9
52	<p>Trends in Micronutrient Laboratory Testing in Switzerland: A 7-Year Retrospective Analysis of Healthcare Claims Data</p> . International Journal of General Medicine, 2020, Volume 13, 1341-1348.	1.8	9
53	Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland. Swiss Medical Weekly, 2020, 150, w20210.	1.6	9
54	Reversal of Dabigatran Using Idarucizumab in a Septic Patient with Impaired Kidney Function in Real-Life Practice. Case Reports in Emergency Medicine, 2016, 2016, 1-3.	0.3	8

#	Article	IF	CITATIONS
55	Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale. Journal of Cardiovascular Translational Research, 2021, 14, 110-119.	2.4	7
56	Predicting Recurrent Venous Thromboembolism in Patients With Deep-Vein Thrombosis: Development and Internal Validation of a Potential New Prediction Model (Continu-8). Frontiers in Cardiovascular Medicine, 2021, 8, 655226.	2.4	7
57	Current Knowledge on Factor V Leiden Mutation as a Risk Factor for Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2022, 9, 883986.	2.4	7
58	Iron Chelation with Deferasirox in Two Patients with HFE Hemochromatosis and Chronic Anemia. Acta Haematologica, 2011, 126, 119-121.	1.4	6
59	Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists. Journal of Thrombosis and Haemostasis, 2017, 15, 2165-2175.	3.8	6
60	Immunoadsorption for the Treatment of Acquired Hemophilia: New Observational Data, Systematic Review, and Meta-Analysis. Transfusion Medicine Reviews, 2021, 35, 125-134.	2.0	6
61	Diagnostic accuracy of SARS-CoV-2 saliva antigen testing in a real-life clinical setting. International Journal of Infectious Diseases, 2022, 119, 38-40.	3.3	6
62	Heparin-induced Thrombocytopenia: Perioperative Diagnosis and Management. Anesthesiology, 2022, 136, 336-344.	2.5	6
63	Diagnostic value of the 4Ts score for heparin-induced thrombocytopenia in the critically ill. Journal of Critical Care, 2014, 29, 1126-1127.	2.2	5
64	System performance evaluation of the cobas t 711 and cobas t 511 coagulation analyzers in routine laboratory settings. Blood Coagulation and Fibrinolysis, 2020, 31, 459-468.	1.0	5
65	Long-Term Survival After Venous Thromboembolism: A Prospective Cohort Study. Frontiers in Cardiovascular Medicine, 2021, 8, 749342.	2.4	5
66	Low COAT platelets are frequent in patients with bleeding disorders of unknown cause (BDUC) and can be enhanced byADDAVP. Journal of Thrombosis and Haemostasis, 2022, 20, 1271-1274.	3.8	5
67	Severe Hyperkalemia and Bilateral Adrenal Metastasis. Journal of Oncology, 2009, 2009, 1-2.	1.3	4
68	Accuracy of the functional, flow cytometer-based Emo-Test HIT Confirm® for the diagnosis of heparin-induced thrombocytopenia. Thrombosis Research, 2021, 203, 22-26.	1.7	4
69	Translating Laboratory Tests into Clinical Practice: A Conceptual Framework. Hamostaseologie, 2020, 40, 420-429.	1.9	4
70	Patient selfâ€management of oral anticoagulation with vitamin K antagonists in everyday practice: comment on Jennings, <i>etÂal</i> British Journal of Haematology, 2014, 167:600–607. British Journal of Haematology, 2015, 169, 600-601.	2.5	3
71	Thromboelastometry as a diagnostic tool in mild bleeding disorders. European Journal of Anaesthesiology, 2019, 36, 457-465.	1.7	3
72	Utility of the Platelet Function Analyzer in Patients with Suspected Platelet Function Disorders: Diagnostic Accuracy Study. TH Open, 2020, 04, e427-e436.	1.4	3

MICHAEL NAGLER

#	Article	IF	CITATIONS
73	Orthotopic Liver Transplant in a Patient Anticoagulated With Rivaroxaban: A Case Report. A&A Practice, 2019, 13, 54-57.	0.4	2
74	Falls in ED patients: do elderly patients on direct oral anticoagulants bleed less than those on vitamin K antagonists?. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2021, 29, 56.	2.6	2
75	Thromboelastometry changes in myeloproliferative neoplasms—surrogate for a procoagulant haemostatic imbalance or a consequence of technical reasons?. Annals of Hematology, 2014, 93, 1781-1782.	1.8	1
76	Adherence to treatment with non-vitamin K antagonist anticoagulants: once- vs. twice-daily regimens. Europace, 2015, 17, 1316.1-1316.	1.7	1
77	Shorter Hospital Stay and Fewer Hospitalizations in Patients With Visible Hematuria on Direct Oral Anticoagulants Compared to on Vitamin K Antagonists. Urology, 2019, 132, 101-108.	1.0	1
78	Impaired kidney function at ED admission: a comparison of bleeding complications of patients with different oral anticoagulants. BMC Emergency Medicine, 2021, 21, 105.	1.9	1
79	Prothrombinase-Induced Clotting Time to Measure Drug Concentrations of Rivaroxaban, Apixaban, and Edoxaban in Clinical Practice: A Cross-Sectional Study. Life, 2022, 12, 1027.	2.4	1
80	Leeching as a substitute for phlebotomy. British Journal of Haematology, 2011, 153, 420-420.	2.5	0
81	Response by Gargiulo et al to Letter Regarding Article, "Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial― Circulation, 2021, 143, e797-e798.	1.6	0
82	Accuracy of the STA®-Liquid anti-Xa assay in clinical practice: results from a large cross-sectional study in Switzerland. , 2021, 41, .		0
83	A universal anti-Xa assay for the determination of rivaroxaban, apixaban, and edoxaban drug levels: development, diagnostic accuracy, and external validation. , 2021, 41, .		0
84	Changing Perspectives of Local Therapists Eight Years after the Implementation of an Occupational Therapy Service in a Unique Himalayan Cross-Cultural Setting. Occupational Therapy International, 2021, 2021, 1-13.	0.7	0
85	A Universal Anti-Xa Assay for the Determination of Rivaroxaban and Apixaban Plasma Concentrations: An In vitro Investigation and Evaluation Study in Real-life Clinical Practice. , 2019, 39, .		0
86	Risk of Recurrence after Stopping Anticoagulants in Women with Combined Oral Contraceptive-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 776-776.	1.4	0
87	Rational development and application of biomarkers in the field of autoimmunity: A conceptual framework guiding clinicians and researchers. Journal of Translational Autoimmunity, 2022, 5, 100151.	4.0	0